Edluar® - treatment of short-term insomnia

Edluar® is based on Orexo’s sublingual tablet technology and the active substance zolpidem. The product offers treatment for short-term insomnia. Zolpidem is a well-documented substance that has been used in the treatment of insomnia for a long time. The Edluar® tablet is placed under the tongue, where it rapidly dissolves and the active ingredient is absorbed through the mucous membrane.

Short facts  
Technology Sublingual
Indication Insomnia
Market approvals US, EU
Commercial right Worldwide Mylan
Partner

Patent protection

US until 2031. EU until 2015.

Edluar® was approved by the US Food and Drug Administration, FDA, in March 2009. In June 2012 Edluar® was approved for registration in Europe.